Along with NRAS, Crohn’s and Colitis UK and the Psoriasis Association, NASS want to understand your experiences of switching to a biosimilar medication.
We are running two separate surveys.
One will trace your experiences of the Humira biosimilar switch and the other will trace your experiences of the Enbrel biosimilar switch, which mainly happened a couple of years ago.
Both surveys will look at your experience from the viewpoint of the information provided by your hospital and your experience of the biosimilar product itself. From these surveys we really hope to provide an accurate picture at what’s happening within the UK with regard to biosimilar switching.
The final results will be presented to NHS England, healthcare professionals and, of course, NASS members and supporters.
If you have been switched from Enbrel to biosimilar Benepali or Erelzi please click this link to get to the survey
If you have been switched from Humira to biosimilar Amgevita, Hulio, Hyrimoz or Imraldi please click this link to get to the survey.
To really answer accurately, we’d rather you wait until you’ve been on the biosimilar for 12 weeks (or 6 injections). We will keep the survey open for quite a few months so you should have plenty of time to get involved.
If you have any questions please do email email@example.com
Sally presented the preliminary survey results at the Westminster Health Forum policy conference on 16 July 2019.